Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794925 | 1.00 | HDAC8 (0.63) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154200 | 1.00 | HDAC8 (0.63) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154405 | 0.91 | HDAC8 (0.67) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154404 | 0.91 | HDAC8 (0.67) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL29698966 | 0.91 | HDAC8 (0.67) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL29699006 | 0.91 | HDAC8 (0.64) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154224 | 0.91 | HDAC8 (0.64) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154226 | 0.91 | HDAC8 (0.64) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL31442472 | 0.90 | HDAC8 (0.65) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL18154254 | 0.90 | HDAC8 (0.65) | HDAC8HDAC6HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-11052070-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | HDAC8 1051/4885HDAC6 562/4885HDAC3 204/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | HDAC8 968/4885HDAC6 582/4885HDAC3 970/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | HDAC8 1011/4885HDAC6 566/4885HDAC3 211/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-11052070-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | HDAC8 1019/4885HDAC6 610/4885HDAC3 901/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | HDAC8 968/4885HDAC6 582/4885HDAC3 970/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | HDAC8 968/4885HDAC6 582/4885HDAC3 970/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | HDAC8 854/4885HDAC6 477/4885HDAC3 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.